Soligenix (SNGX) Restructuring Costs (2010 - 2011)
Soligenix's (SNGX) quarterly Restructuring Costs came in at $25198.0 in Q2 2011, up 22.0% YoY from $20654.0 in Q2 2010, and up 22.0% on a QoQ basis from $20654.0 in Q2 2010.
Soligenix (SNGX) Restructuring Costs (2010 - 2011) Analysis & Trends
Soligenix (SNGX) has 2 years of Restructuring Costs data on file, last reported at $25198.0 in Q2 2011.
- Quarterly Restructuring Costs rose 22.0% year-over-year to $25198.0 in Q2 2011, while the trailing twelve-month figure through Dec 2020 was $45852.0 (changed N/A YoY) and the FY2020 annual result came in at $5.0 million, changed N/A from the prior year.
- Restructuring Costs improved to $25198.0 in Q2 2011, from $20654.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $25198.0 in Q2 2011 to a low of $20654.0 in Q2 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - |
| 10 | Soligenix | 6.30 Mn | 6.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2011 | 25,198.00 |
| Jun 30, 2010 | 20,654.00 |